New Drug Combination to Treat COVID-19

Severe or critical COVID-19 cases can be treated using the combination of drugs along with corticosteroids.

Patients with COVID-19 can be treated with two new drugs as per a WHO (World Health Organisation) Guideline Development Group of international experts in The BMJ.

The drug baricitinib (a type of drug known as a Janus kinase (JAK) inhibitor, also used to treat rheumatoid arthritis) was strongly recommended along with combination with corticosteroids for patients with severe or critical COVID-19.

FDA Authorizes Merck's At-home COVID-19 Drug
The US Food and Drug Administration has authorized Merck's second anti-viral drug Molnupiravir, revealed sources. The report said that the prescription pill can be taken at home.

‘Severe or critical COVID-19 cases can be treated using a combination of drugs along with corticosteroids.’

Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation, with no observed increase in adverse effects.

The WHO experts note that baricitinib has similar effects to other arthritis drugs called interleukin-6 (IL-6) inhibitors so when both are available, they suggest choosing one based on cost, availability, and clinician experience. It is not recommended to use both drugs at the same time.

However, the experts advise against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) for patients with severe or critical COVID-19 because low certainty evidence from small trials failed to show benefit and suggests a possible increase in serious side effects with tofacitinib.

Commercial COVID-19 Drug Production In India
Biocon Biologics signed a pact with Adagio Therapeutics for manufacturing antibody-based COVID-19 treatment that can effectively neutralize a broad range of COVID-19 variants in India.

In the same guideline update, WHO also makes a conditional recommendation for the use of the monoclonal antibody sotrovimab in patients with non-severe COVID-19, but only in those at highest risk of hospitalization, reflecting trivial benefits in those at lower risk.

A similar recommendation has been made by WHO for another monoclonal antibody drug (casirivimab-imdevimab). The experts also note that there were insufficient data to recommend one monoclonal antibody treatment over another - and they acknowledge that their effectiveness against new variants like omicron is still uncertain.

New Radical COVID-19 Drug Development Approach Holds Promise
University of Washington's Baker Lab uses de novo computational design on TACC systems to create new therapeutic approach for treating novel coronavirus.

As such, they say guidelines for monoclonal antibodies will be updated when additional data become available.

Today’s recommendations are based on new evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical COVID-19 infection.

They are part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide trustworthy guidance on the management of COVID-19 and help doctors make better decisions with their patients.

Living guidelines are useful in fast-moving research areas like COVID-19 because they allow researchers to update previously vetted and peer-reviewed evidence summaries as new information become available.

To make their recommendations, the panel considered a combination of evidence assessing relative benefits and harms, values and preferences, and feasibility issues.

Today’s guidance adds to previous recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids for patients with severe or critical COVID-19; conditional recommendations for the use of casirivimab-imdevimab (another monoclonal antibody treatment) in selected patients; and against the use of convalescent plasma, ivermectin and hydroxychloroquine in patients with COVID-19 regardless of disease severity.

Source-Eurekalert